Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in Moldova has been experiencing steady growth in recent years.
Customer preferences: Moldova's healthcare system has been improving, leading to an increase in demand for immunosuppressants. Patients suffering from autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis are the primary consumers of these drugs. Additionally, the aging population in Moldova has also contributed to the growth of the market, as older individuals are more susceptible to these types of diseases.
Trends in the market: One trend that has been observed in the Moldovan market is the increasing use of biologics as immunosuppressants. Biologics are medications that are made from living cells and are designed to target specific parts of the immune system. They are often more effective than traditional immunosuppressants and have fewer side effects. Another trend is the rise of generic immunosuppressants, which are more affordable than their brand-name counterparts.
Local special circumstances: Moldova is a small country with a population of just over 4 million people. Its healthcare system is still developing, and many patients struggle to access the medications they need. This has led to an increase in the number of counterfeit drugs on the market, which can be dangerous for patients. The government has been working to combat this issue by implementing stricter regulations and increasing public awareness.
Underlying macroeconomic factors: Moldova is one of the poorest countries in Europe, with a GDP per capita of just over $2,000. This has led to a lack of investment in the healthcare sector, making it difficult for patients to access the medications they need. However, the government has been working to improve the healthcare system, and the market for immunosuppressants is expected to continue growing as a result. Additionally, Moldova is a member of the European Union's Eastern Partnership program, which aims to promote economic development and integration with the rest of Europe. This could lead to increased investment in the healthcare sector and further growth in the immunosuppressants market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
